<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1012497</article-id><article-id pub-id-type="publisher-id">ACM-39603</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201200000_21304303.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  Caprini静脉血栓风险评估模型在血液肿瘤伴中心静脉血栓患者中的有效性
  Effectiveness of Caprini Venous Thrombosis Risk Assessment Model in Patients with Hematologic Malignancies and Central Venous Thrombosis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>高</surname><given-names>丽霞</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>许</surname><given-names>风雷</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>胡</surname><given-names>军</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>程</surname><given-names>纬</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>贾</surname><given-names>晓玲</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>菅</surname><given-names>辉玲</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff4"><addr-line>新疆克拉玛依市中心医院血液肿瘤科，新疆 克拉玛依</addr-line></aff><aff id="aff3"><addr-line>新疆克拉玛依市中心医院神经内科，新疆 克拉玛依</addr-line></aff><aff id="aff2"><addr-line>新疆克拉玛依市中心医院血液肿瘤科，新疆 克拉玛依 </addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>12</month><year>2020</year></pub-date><volume>10</volume><issue>12</issue><fpage>3324</fpage><lpage>3330</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：分析Cabrini评估量表在血液病肿瘤患者深静脉血栓(DVT)的预测价值及有效性。方法：采用回顾性研究方法，选取：2014年6月~2019年6月克拉玛依市中心医院收治的血液病肿瘤患者3487例，收集患者一般资料，深静脉事件数，Caprini模型的40个危险因素，并进行Caprini模型评分、血栓发生风险分层，统计分析其相关性。结果：本研究纳入的1656例血液肿瘤患者中，发生下肢深静脉血栓174例(10.51%)；DVT (102例)和非DVT (72例)两组患者一般资料调查结果均无显著差异；DVT患者Caprini评分(12.56 &#177; 3.721)高于非DVT (6.72 &#177; 2.89)，差异有统计学意义(P &lt; 0.01)；DVT风险均为高危及以上等级，极高危患者所占比例最高，达到98.04%，与低危组患者相比，极高危组患者DVT风险显著增高，表明Caprini评分与静脉血栓形成具有较好相关性。结论：Caprini静脉血栓风险评估可以较好的预测肿瘤患者下肢深静脉血栓的发生，临床实用性强。
    Objective: To analyze the predictive value and validity of Caprini assessment scale in deep venous thrombosis (DVT) of hematologic tumor patients. Methods: A retrospective study method was used to select 3487 patients with hematologic diseases and tumor admitted to Karamay Central Hospital from June 2014 to June 2019. The general data of patients, the number of deep venous events, and 40 risk factors of Caprini model were collected. The Caprini model score and the risk stratification of thrombosis were statistically analyzed. Result: In 1656 patients with hematological malignancies, 174 cases (10.51%) had lower extremity deep venous thrombosis; there was no significant difference in general information survey results between DVT (102 cases) and non-DVT (72 cases); Caprini score of DVT patients (12.56 &#177; 3.721) was higher than that of non-DVT (6.72 &#177; 2.89), the difference was statistically significant (P &lt; 0.01). Compared with the low-risk group, the risk of DVT in the extremely high-risk group was significantly higher than that in the low-risk group, indicating that there was a good correlation between Caprini score and venous thrombosis. Conclusion: Caprini venous thrombosis risk assessment can better predict the occurrence of lower extremity deep vein thrombosis in tumor patients, and has strong clinical practicability. 
  
 
</p></abstract><kwd-group><kwd>肿瘤，深静脉血栓，Caprini评分, Tumor</kwd><kwd> Deep Vein Thrombosis</kwd><kwd> Caprini Score</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：分析Cabrini评估量表在血液病肿瘤患者深静脉血栓(DVT)的预测价值及有效性。方法：采用回顾性研究方法，选取：2014年6月~2019年6月克拉玛依市中心医院收治的血液病肿瘤患者3487例，收集患者一般资料，深静脉事件数，Caprini模型的40个危险因素，并进行Caprini模型评分、血栓发生风险分层，统计分析其相关性。结果：本研究纳入的1656例血液肿瘤患者中，发生下肢深静脉血栓174例(10.51%)；DVT (102例)和非DVT (72例)两组患者一般资料调查结果均无显著差异；DVT患者Caprini评分(12.56 &#177; 3.721)高于非DVT (6.72 &#177; 2.89)，差异有统计学意义(P &lt; 0.01)；DVT风险均为高危及以上等级，极高危患者所占比例最高，达到98.04%，与低危组患者相比，极高危组患者DVT风险显著增高，表明Caprini评分与静脉血栓形成具有较好相关性。结论：Caprini静脉血栓风险评估可以较好的预测肿瘤患者下肢深静脉血栓的发生，临床实用性强。</p></sec><sec id="s2"><title>关键词</title><p>肿瘤，深静脉血栓，Caprini评分</p></sec><sec id="s3"><title>Effectiveness of Caprini Venous Thrombosis Risk Assessment Model in Patients with Hematologic Malignancies and Central Venous Thrombosis</title><p>Lixia Gao<sup>1*</sup>, Fenglei Xu<sup>2</sup>, Jun Hu<sup>1</sup>, Wei Cheng<sup>1</sup>, Xiaoling Jia<sup>1</sup>, Huiling Jian<sup>1</sup></p><p><sup>1</sup>Department of Hematology and Oncology, Karamay Central Hospital, Karamay Xinjiang</p><p><sup>2</sup>Department of Neurology, Karamay Central Hospital, Karamay Xinjiang</p><p><img src="//html.hanspub.org/file/67-1571783x5_hanspub.png" /></p><p>Received: Nov. 27<sup>th</sup>, 2020; accepted: Dec. 24<sup>th</sup>, 2020; published: Dec. 31<sup>st</sup>, 2020</p><p><img src="//html.hanspub.org/file/67-1571783x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To analyze the predictive value and validity of Caprini assessment scale in deep venous thrombosis (DVT) of hematologic tumor patients. Methods: A retrospective study method was used to select 3487 patients with hematologic diseases and tumor admitted to Karamay Central Hospital from June 2014 to June 2019. The general data of patients, the number of deep venous events, and 40 risk factors of Caprini model were collected. The Caprini model score and the risk stratification of thrombosis were statistically analyzed. Result: In 1656 patients with hematological malignancies, 174 cases (10.51%) had lower extremity deep venous thrombosis; there was no significant difference in general information survey results between DVT (102 cases) and non-DVT (72 cases); Caprini score of DVT patients (12.56 &#177; 3.721) was higher than that of non-DVT (6.72 &#177; 2.89), the difference was statistically significant (P &lt; 0.01). Compared with the low-risk group, the risk of DVT in the extremely high-risk group was significantly higher than that in the low-risk group, indicating that there was a good correlation between Caprini score and venous thrombosis. Conclusion: Caprini venous thrombosis risk assessment can better predict the occurrence of lower extremity deep vein thrombosis in tumor patients, and has strong clinical practicability.</p><p>Keywords:Tumor, Deep Vein Thrombosis, Caprini Score</p><disp-formula id="hanspub.39603-formula82"><graphic xlink:href="//html.hanspub.org/file/67-1571783x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/67-1571783x8_hanspub.png" /> <img src="//html.hanspub.org/file/67-1571783x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>静脉血栓栓塞症(venous thromboembolism, VTE)有较高的病死率，生存时间明显缩 [<xref ref-type="bibr" rid="hanspub.39603-ref1">1</xref>]。血液肿瘤是公认导致VTE的继发性危险因素(占第二位20.3%)，仅次于外伤/手术。DVT的早期筛查和评估对防治VTE，具有极其重要的价值 [<xref ref-type="bibr" rid="hanspub.39603-ref2">2</xref>]。血液肿瘤科患者病情较为复杂，且多伴有并发症，使得对静脉血栓栓塞症风险难以预防和评估。Caprini评分 [<xref ref-type="bibr" rid="hanspub.39603-ref3">3</xref>] 对于此类患者尤其是术后患者的VTE风险的临床预测具有较高的价值。本研究对本院血液肿瘤患者采用2010版Caprini风险评估量表进行评分，B超声筛查下肢深静脉血栓，为防治患者VTE风险提供有效依据。</p></sec><sec id="s6"><title>2. 资料及方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>本研究采用进行回顾性、病例对照研究。本研究通过克拉玛依市中心医院医院伦理委员会批准。收集2014年6月~2019年6月克拉玛依市中心医院血液肿瘤患者进行调查，应用B超声筛查下肢深静脉明确有无下肢深静脉血栓。共1656例符合纳入标准 [<xref ref-type="bibr" rid="hanspub.39603-ref4">4</xref>]。</p></sec><sec id="s6_2"><title>2.2. 研究工具</title><p>Caprini模型：参照2010年Caprini模型修订版，收集研究对象的40个静脉血栓危险因素，并对各危险因素进行均赋值计算Caprini模型得分，并对研究对象进行静脉血栓发生风险分层：0~1分为低危，2分为中危，3~4分为高危，≥5分为极高危 [<xref ref-type="bibr" rid="hanspub.39603-ref5">5</xref>]。</p></sec><sec id="s6_3"><title>2.3. 研究方法</title><p>对所有纳入研究的患者：① 收集患者性别、年龄、吸烟史、合并慢性病如高血压、糖尿病、冠心病等以及患者人院时的血小板计数和D-二聚体实验室检查结果；② 在人院时，护理人员完成Caprini风险评估量表，并进行风险分层预警；③ 入院48 h内，由超声科专业医生进行下肢超声的影像学检查，诊断下肢深静脉血栓的形成；根据影像学检查，将患者分为两组：DVT组和非DVT组。统计录入所有纳入患者B超结果及静脉血栓发生事件。</p></sec><sec id="s6_4"><title>2.4. 统计学方法</title><p>采用SPSS 18.0软件进行统计学分析。计量资料符合正态分布用 x &#175; &#177; s 表示；计数资料用率(%)表示。正态分布计量资料两组比较采用独立样本t检验，非正态分布的计量资料两组比较采用非参数Mann-Whitnev U检验；两组计数资料比较采用卡方检验。以P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><p>1) 患者一般情况比较：DVT组与非DVT组在的性别、平、年龄、吸烟史、高血压、心血管疾病、糖尿病合并情况，血小板、D-二聚体计数差异无统计学意义(P &gt; 0.05) (表1)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> General information of patients in DVT group and non-DVT grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >项目</th><th align="center" valign="middle" >DVT组(102)</th><th align="center" valign="middle" >非DVT组(72例)</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >年龄(岁 x &#175; &#177; s )</td><td align="center" valign="middle" >62.1 &#177; 8.32</td><td align="center" valign="middle" >61.4 &#177; 10.25</td><td align="center" valign="middle" >0.623</td></tr><tr><td align="center" valign="middle" >男性(例%)</td><td align="center" valign="middle" >67 (65.7)</td><td align="center" valign="middle" >45 (62.5)</td><td align="center" valign="middle" >0.215</td></tr><tr><td align="center" valign="middle" >吸烟(例%)</td><td align="center" valign="middle" >54 (48.2)</td><td align="center" valign="middle" >38 (52.7)</td><td align="center" valign="middle" >0.786</td></tr><tr><td align="center" valign="middle" >ECOGPS (分 x &#175; &#177; s )</td><td align="center" valign="middle" >2.1 &#177; 1.3<sup>*</sup></td><td align="center" valign="middle" >1.59 &#177; 1.1</td><td align="center" valign="middle" >0.002</td></tr><tr><td align="center" valign="middle" >高血压病</td><td align="center" valign="middle" >19 (18.6)</td><td align="center" valign="middle" >8 (11.1)</td><td align="center" valign="middle" >1.542</td></tr><tr><td align="center" valign="middle" >心血管疾病</td><td align="center" valign="middle" >8 (7.4)</td><td align="center" valign="middle" >4 (5.6)</td><td align="center" valign="middle" >1.124</td></tr><tr><td align="center" valign="middle" >糖尿病</td><td align="center" valign="middle" >11 (10.8)</td><td align="center" valign="middle" >6 (8.3)</td><td align="center" valign="middle" >1.234</td></tr><tr><td align="center" valign="middle" >VTE的预防(n, %)</td><td align="center" valign="middle" >27 (37.5)<sup>*</sup></td><td align="center" valign="middle" >80 (55.56)</td><td align="center" valign="middle" >0.010</td></tr><tr><td align="center" valign="middle" >血小板计数(&#215;10<sup>9</sup>/L)</td><td align="center" valign="middle" >265.18 &#177; 33.66</td><td align="center" valign="middle" >201.21 &#177; 45.06</td><td align="center" valign="middle" >0.856</td></tr><tr><td align="center" valign="middle" >D-二聚体计数(ug/mL)</td><td align="center" valign="middle" >0.36 &#177; 0.35</td><td align="center" valign="middle" >0.29 &#177; 0.12</td><td align="center" valign="middle" >0.965</td></tr></tbody></table></table-wrap><p>表1. DVT组与非DVT组患者的一般情况</p><p>注：DVT组与非DVT组比较，<sup>*</sup>P &lt; 0.05；Note: compared with non-DVT group, <sup>*</sup>P &lt; 0.05.</p><p>2) 两组患者Caprini模型危险因素的比较：Caprini模型的40个危险因素中有20个危险因素(异常妊娠、口服避孕药、脓毒血症等)两组患者病例均不具备，小手术这1个危险因素两组所有病例均具备，抗心磷脂抗体、狼疮抗凝物、凝血酶原20210A、凝血因子V Leiden，VTE家族史这5个危险因素所有病例均无数据。剩下的12个危险因素DVT组与非DVT组差异均无统计学意义(均P &gt; 0.05)，见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of risk factors of Caprini model between DVT group and non-DVT grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >危险因素分值</th><th align="center" valign="middle" >DVT组(102)</th><th align="center" valign="middle" >非DVT组(72例)</th><th align="center" valign="middle" >X<sup>2</sup></th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >40~61岁[例%]</td><td align="center" valign="middle" >28 (27.5)</td><td align="center" valign="middle" >15 (20.8)</td><td align="center" valign="middle" >0.169</td><td align="center" valign="middle" >0.658</td></tr><tr><td align="center" valign="middle" >小手术(&lt;45 min) [例%]</td><td align="center" valign="middle" >102 (100)</td><td align="center" valign="middle" >72 (100)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >BMI &gt; 25 kg/m<sup>2</sup> [例%]</td><td align="center" valign="middle" >4 (3.9)</td><td align="center" valign="middle" >2 (2.8)</td><td align="center" valign="middle" >0.721</td><td align="center" valign="middle" >0.451</td></tr><tr><td align="center" valign="middle" >下肢水肿[例%]</td><td align="center" valign="middle" >29 (28.4)</td><td align="center" valign="middle" >13 (22.2)</td><td align="center" valign="middle" >0.169</td><td align="center" valign="middle" >0.658</td></tr><tr><td align="center" valign="middle" >下肢静脉曲张[例%]</td><td align="center" valign="middle" >1 (0.9)</td><td align="center" valign="middle" >0 (0.0)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >0.362</td></tr><tr><td align="center" valign="middle" >妊娠期或产褥期[例%]</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >习惯性流产史(&gt;3次) [例%]</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >口服避孕药或雌激素代替[例%]</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >脓毒血症(&lt;1个月) [例%]</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >严重肺炎(&lt;1个月) [例%]</td><td align="center" valign="middle" >119 (18.6)</td><td align="center" valign="middle" >8 (11.1)</td><td align="center" valign="middle" >1.246</td><td align="center" valign="middle" >0.164</td></tr><tr><td align="center" valign="middle" >肺功能异常(FEV1 &lt; 50%) [例%]</td><td align="center" valign="middle" >112 (11.7)</td><td align="center" valign="middle" >4 (5.6)</td><td align="center" valign="middle" >1.983</td><td align="center" valign="middle" >0.186</td></tr><tr><td align="center" valign="middle" >心力衰竭(&lt;1个月) [例%]</td><td align="center" valign="middle" >113 (12.7)</td><td align="center" valign="middle" >5 (6.9)</td><td align="center" valign="middle" >1.107</td><td align="center" valign="middle" >0.096</td></tr><tr><td align="center" valign="middle" >炎性肠病史[例%]</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >因内科疾病卧床(&lt;72 h) [例%]</td><td align="center" valign="middle" >1 0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >年龄61~74岁[例%]</td><td align="center" valign="middle" >232 (31.37)</td><td align="center" valign="middle" >22 (30.56)</td><td align="center" valign="middle" >1.523</td><td align="center" valign="middle" >0.291</td></tr><tr><td align="center" valign="middle" >腹腔镜手术(&gt;45 min) [例%]</td><td align="center" valign="middle" >200</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >其他大手术(&gt;45 min) [例%]</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >卧床时间(&gt;72 h) [例%]</td><td align="center" valign="middle" >200</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >中心静脉置管[例%]</td><td align="center" valign="middle" >236 (35.5)</td><td align="center" valign="middle" >20 (27.8)</td><td align="center" valign="middle" >1.745</td><td align="center" valign="middle" >0.536</td></tr><tr><td align="center" valign="middle" >年龄 ≥ 75岁[例%]</td><td align="center" valign="middle" >342 (41.2)</td><td align="center" valign="middle" >35 (48.6)</td><td align="center" valign="middle" >1.634</td><td align="center" valign="middle" >0.459</td></tr><tr><td align="center" valign="middle" >VTE家族史[例%]</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >肝素诱导的血小板减少症[例%]</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >抗心磷脂抗体[例%]</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >狼疮抗凝物阳性[例%]</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >凝血因子V Leiden突变[例%]</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >血清Hcy水平升高[例%]</td><td align="center" valign="middle" >322 (21.6)</td><td align="center" valign="middle" >16 (22.2)</td><td align="center" valign="middle" >0.083</td><td align="center" valign="middle" >0.895</td></tr><tr><td align="center" valign="middle" >凝血酶原2021OA基因变异[例%]</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >脑卒中(&lt;1个月) [例%]</td><td align="center" valign="middle" >55 (4.9)</td><td align="center" valign="middle" >2 (2.7)</td><td align="center" valign="middle" >0.883</td><td align="center" valign="middle" >0.257</td></tr><tr><td align="center" valign="middle" >急性骨髓损伤(&lt;1个月) [例%]</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >髋关节骨盆或下肢多发骨折[例%]</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr></tbody></table></table-wrap><p>表2. DVT组与非DVT组Caprini模型危险因素的比较</p><p>注：BMI：体重指数；其他高危因素为糖尿病史等；VTE：静脉血栓栓塞；PE：肺栓塞；“-”为无数据。Note: BMI: body mass index; other high risk factors are diabetes history; VTE: venous thromboembolism; PE: pulmonary embolism; “-” means no data.</p><p>3) 患者Caprini评分及危险度分级比较：病例组患者Caprini评分(12.56 &#177; 3.721)高于对照组(6.72 &#177; 2.89)，差异有统计学意义(P &lt; 0.01)；病例组的危险等级分布中，DVT风险均为高危及以上等级，极高危患者所占比例最高，达到98.04%，对照组中同样极高危患者所占比例最多，其次为高危、中危和低危，两组危险等级构成之间差异有统计学意义(P &lt; 0.01，表3)。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of Caprini score and risk classification between DVT group and non-DVT grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >类别</th><th align="center" valign="middle" >DVT组(102)</th><th align="center" valign="middle" >非DVT (72例)</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >Caprini评分</td><td align="center" valign="middle" >12.56 &#177; 3.72</td><td align="center" valign="middle" >6.72 &#177; 2.89</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >危险度(n, %)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >低危(0~1分) 0 (0%)</td><td align="center" valign="middle" >0 (0%)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >中危(2分)</td><td align="center" valign="middle" >0 (0%)</td><td align="center" valign="middle" >0 (0%)</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >高危(3~4分)</td><td align="center" valign="middle" >2 (1.96%)</td><td align="center" valign="middle" >5 (6.94%)</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >极高危(≥5分)</td><td align="center" valign="middle" >100 (98.04%)</td><td align="center" valign="middle" >67 (93.06)</td><td align="center" valign="middle" >-</td></tr></tbody></table></table-wrap><p>表3. DVT组与非DVT组 Caprini评分及危险度分级比较</p><p>4) Caprini风险评估模型风险等级与VTE发病风险的关系病例组中依据Caprini评分风险等级为极高危(评分 ≥ 5分)的患者所占比例高于对照组，差异具有统计学意义(P &lt; 0.05)，并且极高危患者发生VTE的风险是非极高危患者的18倍(95% CI: 2.461~118.845) (表4)。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Relationship between risk level of Caprini risk assessment model and risk of VT</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle"  colspan="2"  >风险等级</th><th align="center" valign="middle"  rowspan="2"  >OR值</th><th align="center" valign="middle"  rowspan="2"  >95% CI</th><th align="center" valign="middle"  rowspan="2"  >P值</th></tr></thead><tr><td align="center" valign="middle" >非极高危(n, %)</td><td align="center" valign="middle" >极高危(n, %)</td></tr><tr><td align="center" valign="middle" >病例组(n = 102)</td><td align="center" valign="middle" >2 (1.9%)</td><td align="center" valign="middle" >71 (98.1%)</td><td align="center" valign="middle" >18.000</td><td align="center" valign="middle" >2.461~118.845</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >对照组(n = 72)</td><td align="center" valign="middle" >17 (23.6%)</td><td align="center" valign="middle" >55 (76.4)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr></tbody></table></table-wrap><p>表4. Caprini风险评估模型风险等级与VTE发病风险的关系</p></sec><sec id="s8"><title>4. 讨论</title><p>深静脉血栓因其高发病率、高死亡率，已成为世界性的公共健康命题。同时这一疾病也被认为是一种最有可能预防的致死性疾病 [<xref ref-type="bibr" rid="hanspub.39603-ref6">6</xref>]。因此采用简单方便、经济实用、有效的预测评估工具来筛选高危人群，并根据危险级别采取预防措施尤为重要。Caprini模型通过对静脉血栓所占比重的40个危险因素分别赋分值，累加得到总分并对血栓发生风险进行分层，从而预测患者血栓形成的发生概率：低中危层占10%~20%，高危层20%~40%，极高危层40%~80% [<xref ref-type="bibr" rid="hanspub.39603-ref7">7</xref>]。</p><p>临床上通过使用Caprini血栓风险评估模型，根据可得评分划分患者的VTE危险等级，进而对患者的危险因素状况进行评分 [<xref ref-type="bibr" rid="hanspub.39603-ref8">8</xref>]。本研究共纳入174例患者，DVT组(102例)和非DVT组(72例)的Caprini模型评分分值均在3分以上，提示所纳入患者均为发生静脉血栓的高危人群。进一步对高危极高危患者进行分层研究后，发现随危险评分增高，发生VTE的风险增加更明显。原因分析如下：首先，该模型所包含的静脉血栓危险因素较全面，且小手术这个1分的危险因素本研究所有对象均具备；其次，模型将年龄分为3个阶段，赋值随年龄段增加而增加：41~60岁：1分，61~74岁：2分，75岁以上：3分，本研究中61岁以上患者达131例，占75.65%，年龄水平较高；最后中心静脉置管史、血清Hcy水平升高在模型中被赋予2及3分的分值，本研究所纳入的患者因放化疗及化疗后恶心呕吐引发血流动力学改变、中心静脉置管留置等原因更易发生高凝状态最终导致深静脉血栓及肺栓塞 [<xref ref-type="bibr" rid="hanspub.39603-ref9">9</xref>]，本研究显示，Caprini风险评估模型在血液肿瘤患者中也同样适用，Caprini得分值较高，也验证了Cabrini模型可作为筛选静脉血栓高危人群一种高效精准的方式。</p><p>本研究结果表明Caprini风险评估模型在这一研究人群中预测VTE发生的有效性，与国外关于Caprini风险评估模型在外科住院患者中的验证研究结果基本一致 [<xref ref-type="bibr" rid="hanspub.39603-ref10">10</xref>]。周海霞等 [<xref ref-type="bibr" rid="hanspub.39603-ref11">11</xref>] 采用与本研究类似的方法对患者进行回顾性评分及VTE风险分析，发现Caprin模型能有效地区分VTE组及非VTE组病例，并且随着分值的增加，VTE的患病风险也随之增加。而本研究结果显示Caprini模型能将 DVT组及非DVT组进行区分，随着Caprini得分的增加，DVT的发生概率并未表现出与模型预测值一致的增长趋势。</p><p>通过Caprini风险评估模型做出的风险分层，对患者进行相应的预防措施，其中低危患者无需特殊处理，应早期活动 [<xref ref-type="bibr" rid="hanspub.39603-ref12">12</xref>]。中危高危患者实施基本预防，加上物理或药物预防、早期活动联合物理预防或药物预防，物理预防包括间歇式压力充气泵、抗血栓弹力袜等，药物预防排除抗凝禁忌症使用抗凝药物如低分子肝素等；极高危患者则是在基础预防的基础上，物理与药物预防共同实施。根据模型推荐意见对患者实施分层护理预防，可最大限度的保障患者安全，降低患者住院费用。随着DVT预防趋向科学化、标准化、规范化，建立DVT预警和防治体系，规范化管理静脉血栓防治流程，提高DVT早期诊断的特异性敏感性，做到精准预防。</p><p>综上所述，Caprini风险评估模型在筛选极高危患者方面具有良好预测价值 [<xref ref-type="bibr" rid="hanspub.39603-ref13">13</xref>]，可以更好地提高DVT患者检出率，降低高风险患者漏诊率，并能正确识别住院患者DVT发生的高危因素。对患者进行早期风险筛查，从源头上降低DVT的发生率。</p></sec><sec id="s9"><title>基金项目</title><p>新疆自治区自然科学基金项目：2017D01A16。</p></sec><sec id="s10"><title>文章引用</title><p>高丽霞,许风雷,胡 军,程 纬,贾晓玲,菅辉玲. Caprini静脉血栓风险评估模型在血液肿瘤伴中心静脉血栓患者中的有效性Effectiveness of Caprini Venous Thrombosis Risk Assessment Model in Patients with Hematologic Malignancies and Central Venous Thrombosis[J]. 临床医学进展, 2020, 10(12): 3324-3330. https://doi.org/10.12677/ACM.2020.1012497</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.39603-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">中国临床肿瘤学会(CSCO)肿瘤与血栓专家共识委员会. 肿瘤相关静脉血栓栓塞症的预防与治疗中国专家指南(2015版) [J]. 中国肿瘤临床, 2015, 42(20): 979-991.</mixed-citation></ref><ref id="hanspub.39603-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">O’Brien, A., Redley, B., Wood, B., et al. (2018) STOPDVTs: Development and Testing of a Clinical Assessment Tool to Guide Nursing Assessment of Postoperative Patients for Deep Vein Thrombosis. Journal of Clinical Nursing, 27, 1803-1811. &lt;br&gt;https://doi.org/10.1111/jocn.14329</mixed-citation></ref><ref id="hanspub.39603-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Caprini, J.A. (2005) Thrombosis Risk Assessment as a Guide to Quality Patient Care. Disease-a-Month, 51, 70-78.  
&lt;br&gt;https://doi.org/10.1016/j.disamonth.2005.02.003</mixed-citation></ref><ref id="hanspub.39603-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Bahl, V., Hu, H.M., Henke, P.K., et al. (2010) A Validation Study of a Retrospective Venous Thromboembolism Risk Scoring Method. Annals of Surgery, 251, 344-350. &lt;br&gt;https://doi.org/10.1097/SLA.0b013e3181b7fca6</mixed-citation></ref><ref id="hanspub.39603-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Paz Rios, L.H., Fuentes, H.E., Oramas, D.M., et al. (2018) Validation of a Patient-Completed Caprini Risk Assessment Tool for Spanish, Arabic, and Polish Speakers. Clinical and Applied Thrombosis/Hemostasis, 24, 502-512.  
&lt;br&gt;https://doi.org/10.1177/1076029617746505</mixed-citation></ref><ref id="hanspub.39603-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">陈平平, 银锐, 卢瑞春, 等. Caprini血栓风险评估模型筛选脑卒中后深静脉血栓形成的有效性[J]. 中华血管外科杂志, 2017, 2(2): 103-106.</mixed-citation></ref><ref id="hanspub.39603-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Obi, A.T., Pannucci, C.J., Nackashi, A., et al. (2015) Validation of the Caprini Venous Thromboembolism Risk Assessment Model in Critically Ill Surgical Patients. JAMA Surgery, 150, 941-948.  
&lt;br&gt;https://doi.org/10.1001/jamasurg.2015.1841</mixed-citation></ref><ref id="hanspub.39603-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">张汝敏, 王世富, 马爽, 等. PiCCO技术优化脓毒性休克患者EGDT的效果[J]. 中华麻醉学杂志, 2014, 34(6): 739-742.</mixed-citation></ref><ref id="hanspub.39603-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Miller, L.M., MacRae, J.M., Kiaii, M., et al. (2016) Hemodialsis Tunneled Catheter Noninfectious Complications. Canadian Journal of Kidney Health and Disease, 3, 1-10. &lt;br&gt;https://doi.org/10.1177/2054358116669130</mixed-citation></ref><ref id="hanspub.39603-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Pannucci, C.J., Bailey, S.H., Dreszer, G., et al. (2011) Validation of the Caprini Risk Assessment Model in Plastic and Reconstructive Surgery Patients. Journal of the American College of Surgeons, 212, 105-112.  
&lt;br&gt;https://doi.org/10.1016/j.jamcollsurg.2010.08.018</mixed-citation></ref><ref id="hanspub.39603-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">周海霞, 唐永江, 王岚, 等. Caprini风险评估模型筛选内科住院患者静脉血栓栓塞症的有效性[J]. 中华医学杂志, 2013, 93(24): 1864-1867.</mixed-citation></ref><ref id="hanspub.39603-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Lobastov, K., Barinov, V., Schastlivtsev, I., et al. (2016) Validation of the Caprini Risk Assessment Model for Venous Thromboembolism in High-Risk Surgical Patients in the Background of Standard Prophylaxis. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 4, 153-160. &lt;br&gt;https://doi.org/10.1016/j.jvsv.2015.09.004</mixed-citation></ref><ref id="hanspub.39603-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Imbeni, D., Becattini, C., Bemartli, E., et al. (2018) Multidisciplinary Approach to the Management of Patients with Pulmonary Embolism and Deep Vein Thrombosis: A Consensus on Diagnosis, Traditional Therapy and Therapy with Rivaroxaban. Internal and Emergency Medicine, 13, 1037-1049. &lt;br&gt;https://doi.org/10.1007/s11739-018-1802-5</mixed-citation></ref></ref-list></back></article>